Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon May 28, 2021 10:05am
118 Views
Post# 33285330

RE:Exelon & HUGE GROWING UNMET NEED

RE:Exelon & HUGE GROWING UNMET NEED
GoldenInvestor wrote: I'm excited to continue to learn more about the opportunities for Exelon,  

for Alzheimers and Dementia!

with an aging  population, the opportunities to help an ever increasing population is great!

a horrible disease, but it can be better managed with this product!  

& 26 countries to market it in! !!!



Hey Golden ... just a quick calculation on the 26 countries involved.
I used 2019 populations and I assumed the poverty line at 50% for all those countries (closer to 40 but let's stick with 50).
For Canada, I used 30% as the poverty line.

I divide the total population (above the poverty line) by Canada's population (above its poverty line) and we find that Knight's target market has grown from "one Canada" to the equivalent of "12 Canadas"

Not bad ... if you can service them efficiently and with products they need.

Food for thought !

<< Previous
Bullboard Posts
Next >>